AIRSAirSculpt Technologies Inc. Common Stock

Same-center case growth turned positive for second consecutive quarter.

AirSculpt Technologies (AIRS) is back in focus after reporting Q2 2026 results that showed slightly lower sales and a wider net loss, while management reaffirmed full year revenue guidance at the lower end of its range. See our latest analysis for AirSculpt Technologies. The Q2 2026 earnings release and reaffirmed revenue outlook have landed after a period of sharp share price swings for AirSculpt Technologies, with the stock up strongly year to date but total shareholder return over the past...

Despite a 2.5% revenue dip, the company posts its second consecutive quarter of case growth and expands its procedure portfolio to capture the GLP-1 market.

AirSculpt Technologies reported past second-quarter 2026 results showing sales of US$42.9 million versus US$44.01 million a year earlier and a wider net loss of US$1.11 million, while six-month sales slipped to US$82.29 million with a modestly higher cumulative net loss of US$3.51 million. Despite the softer top line and continued losses, the company reaffirmed its full-year 2026 revenue outlook at the lower end of its US$151 million to US$157 million guidance range, signaling management’s...

AirSculpt Technologies (NASDAQ:AIRS) is seeing stabilization in its core body-contouring business after several quarters of declines, while expanding services aimed at patients using GLP-1 weight-loss drugs, Chief Executive Officer Yogi Jashnani said at a Canaccord consumer conference. The company

AirSculpt Technologies (NASDAQ:AIRS) reported second-quarter revenue of $42.9 million, down 2.5% from the prior-year period, as the company cited stable revenue trends, positive same-center case growth and continued investment in marketing and expanded procedure offerings. Chief Executive Officer Y

AirSculpt Technologies, Inc. (NASDAQ:AIRS) shares tumbled 13.